Treatment of Autoimmue Prostatitis with a VDR agonist

Symptoms Physical
#1

Here is the paper:
jimmunol.org/content/177/12/8504.full

Some things to note:

  • mentions prostatitis may be autoimmune, and neurological - involves inflammation
  • mentions why dexa may work, and that a vdr agonist is more effective than dexa (prevention of prostatic infiltrates)
  • mentions that vdr agonist are effective in other immune related diseases - some of which mimic our non-sexual side effects - ie. psoriasis,
  • mentions that prostatic nerves are free of infiltrates when treated with Elocalcitol

Please read the whole article. I believe that a VDR agonist should be tried soon. If (yes, if - i know their are other tests on the AR currently) the cause of our issue is inflammatory or autoimmune, waiting longer for treatments to develop could lead to more inflammation - which can cause further nerve damage or calcification.

#2

I am giving dexamethasone another shot soon. I will let you know if anything comes of it.

#3

If you are just trying things at will i believe benicar would be a wiser choice as it is a vdr agonist, dex has apparently been shown to enhance vd3 transcription, though

ncbi.nlm.nih.gov/pubmed/21868377

#4

Benicar is too expensive.

Dexamethasone showed a lot of promise initially with the reported recovery on the bodybuilding forum, labrea? or someone else off here and one other person. However, myself and Mens rea felt no benefits.

#5

More on VDR agonist, from a different author.
www.uku.fi/vaitokset/2009/isbn978-951-27-1492-5.pdf

The following stood out:

“Pharmacological management of BPH is a novel application of vitamin D analogs, prompted by the detection of VDR expression in cultured prostatic and bladder stromal cells derived from BPH patients (Maggi, Crescioli et al. 2006). Reducing prostate overgrowth by decreasing intra-prostatic androgen signalling, without directly interfering with systemic androgen action, would obviate the adverse systemic side effects of anti-androgens, such as 5α-reductase inhibitors. In addition, VDR agonists display marked anti-inflammatory properties and this class of agents could therefore represent an interesting therapeutic option for the pharmacological treatment of BPH (Maggi, Crescioli et al. 2006).”